Time to first major cytogenetic response (MCyR). (A) Patients with or without a BCR-ABL mutation who received dasatinib treatment at any dose or 100 mg once daily (QD) after resistance or suboptimal response to imatinib. (B) Patients within the total analysis population with commonly mutated amino acids (n ≥ 20).